drugset / Trial / NCT00839397

BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder

NCT00839397

Phase 3 Completed 52 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This was a 52-week, non-comparative, uncontrolled study of paroxetine in Japanese PTSD patients to obtain clinical experience regarding efficacy and safety. In this study, subjects received paroxetine 20mg-40mg once daily after an evening meal.

Timeline

Start
2002-05
Primary completion
2004-11
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Paroxetine Small molecule 20 mg
Subject Paroxetine Small molecule 30 mg
Subject Paroxetine Small molecule 40 mg